↓ Skip to main content

Dove Medical Press

Article Metrics

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache

Overview of attention for article published in Patient preference and adherence, January 2012
Altmetric Badge

Mentioned by

video
1 video uploader

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
21 Mendeley
Title
Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
Published in
Patient preference and adherence, January 2012
DOI 10.2147/ppa.s19171
Pubmed ID
Authors

James Miner, Johanna Moore

Abstract

Subcutaneous sumatriptan is an effective treatment for pain from acute migraine headache, and can be used in patients with known migraine syndrome and in patients with primary headaches when secondary causes have been excluded. In limited comparative trials, subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous metoclopramide, was superior to intravenous aspirin and intramuscular trimethobenzamide-diphenhydramine, and was inferior to intravenous prochlorperazine for pain relief. The most common side effects seen with subcutaneous sumatriptan are injection site reactions and triptan sensations. As with all triptans, there is a risk of rare cardiovascular events with subcutaneous sumatriptan and its use should be limited to those without known cerebrovascular disease and limited in those with known cardiovascular risk factors and unknown disease status. In studies of patient preference and tolerability, the subcutaneous formulation has a faster time of onset and high rate of efficacy when compared with the oral formulation, but the oral formulation appears to be better tolerated. It is important to consider the needs of the patient, their past medical history, and what aspects of migraine treatment are most important to the patient when considering treatment of acute migraine or primary headache. Subcutaneous sumatriptan is a good first-line agent for the treatment of pain from acute migraine headaches and primary headaches.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 24%
Researcher 4 19%
Student > Postgraduate 4 19%
Student > Ph. D. Student 2 10%
Other 2 10%
Other 2 10%
Unknown 2 10%
Readers by discipline Count As %
Medicine and Dentistry 11 52%
Agricultural and Biological Sciences 3 14%
Psychology 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Engineering 1 5%
Other 0 0%
Unknown 4 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2011.
All research outputs
#11,139,014
of 12,522,829 outputs
Outputs from Patient preference and adherence
#976
of 1,052 outputs
Outputs of similar age
#121,160
of 144,731 outputs
Outputs of similar age from Patient preference and adherence
#19
of 23 outputs
Altmetric has tracked 12,522,829 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,052 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,731 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.